ClinicalTrials.gg
CompletedNCT03184324Updated Sep 3, 2020

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)

A Phase 2 interventional study of DWP14012 and Esomeprazole in Erosive Gastroesophageal Reflux Disease, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-03.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.

Enrollment
10th of 52
211 · median 54
Started
2017
with 3 others
Phase 2
5 of 71
none open now
Registered
30th of 71
by date
Lead sponsor
5 of 71
Daewoong Pharmaceutical Co. LTD.

Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 10th largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2017, is one of 5 in phase 2, and was the 30th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of DWP14012 compared to esomeprazole in the treatment of erosive gastroesophageal reflux disease classified as Los Angeles(LA) classification grades A to D.

03

Conditions studied

  • Erosive Gastroesophageal Reflux Disease
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults between 20 and 75 years old based on the date of written agreement
  • Those who have been diagnosed with erosive gastroesophageal reflux disease(EGRD) of LA Grade A-D on the upper gastrointestinal endoscopy
  • Those who experienced symptoms of heartburn or acid reflux within the last 7 days

Exclusion criteria

Exclusion Criteria:

  • Those who have undergone gastric acid suppression or gastric, esophageal surgery
  • Those who with liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    DWP14012 20mg

    DWP14012 20mg, tablet, orally, once daily

    Drug: DWP14012 · Drug: DWP14012 placebo · Drug: Esomeprazole placebo

  • Experimental
    DWP14012 40mg

    DWP14012 40mg, tablet, orally, once daily

    Drug: DWP14012 · Drug: DWP14012 placebo · Drug: Esomeprazole placebo

  • Experimental
    DWP14012 80mg

    DWP14012 40mg\*2, tablet, orally, once daily

    Drug: DWP14012 · Drug: DWP14012 placebo · Drug: Esomeprazole placebo

  • Active comparator
    Esomerpazole 40mg

    Esomerpazole 40mg, tablet, orally, once daily

    Drug: Esomeprazole · Drug: DWP14012 placebo

Interventions

  • tablet

  • tablet

    Also known as: Nexium

  • DrugDWP14012 placebo

    tablet

  • DrugEsomeprazole placebo

    tablet

06

What researchers measure

Primary outcomes

  1. Ratio of subjects who were completely cured of mucosal defects by 8 weeks

    Time frame: 8 weeks

Secondary outcomes

  1. Ratio of subjects who were completely cured of mucosal defects by 4 weeks

    Time frame: 4 weeks

07

Study locations

1 site
  • Hanyang University Medical Center
    Sungdong-gu, Seoul 04763, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Apr 2018, 7 months.

Of 14 phase 2 interventional studies under Gastroesophageal Reflux, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2017
First posted
Jun 12, 2017
StartActual
Aug 28, 2017
Primary completionActual
Apr 18, 2018
CompletionActual
Apr 18, 2018
Last update
Sep 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03184324
Responsible party
Sponsor
First posted
Jun 12, 2017
Start date
Aug 28, 2017
Primary completion
Apr 18, 2018
Completion
Apr 18, 2018
Last update
Sep 3, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion